Trial Profile

The Effect Of Acadesine On Clinically Significant Adverse Cardiovascular and Cerebrovascular Events In High-Risk Subjects Undergoing Coronary Artery Bypass Graft (CABG) Surgery Using Cardiopulmonary Bypass (Protocol No. P05633): RED-CABG Trial (Reduction in Cardiovascular Events by AcaDesine in Subjects Undergoing CABG).

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 10 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acadesine (Primary)
Indications Cardiovascular disorders; Cerebrovascular disorders; Ischaemic stroke
Focus Pharmacogenomic; Registrational; Therapeutic Use
Acronyms RED-CABG
Sponsors Merck Sharp & Dohme Corp.; Schering-Plough; Schering-Plough Research Institute

19 Jun 2019 This trial has been discontinued in France, according to European Clinical Trials Database.
24 May 2019 This trial is completed in Germany according to Eudra
21 Oct 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com